Skip to main content
OpenTrials
Completed

NCT Number: NCT01314690

Human Intestinal Microbiota in Obesity and Nutritional Transition

The objectives of this study are: 1-To qualify the relationship between the gut microbiota and the host nutritional and metabolic status during dietary transition.2-To define the impact of nutritional transition on the intestinal microbiota and identify metagenomics signatures of nutritional transition.

Completed

Looking for future studies?

Notify Me

Key information

Age range

25 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Assistance publique-hopitaux de Paris

Paris, France

About this study

French overweight (BMI > 27) and obese people (BMI > 30 kg/m2, N=50) will be submitted to a low calorie diet (1200 Kcal) for 8 weeks. This type of intervention is know to modify the metabolic phenotype and expected to change the gut microbiota. Nutritional interventions are planned for 6 months, each subject being studied before (base line), after the intervention (8 weeks) and 2 months after the low calorie diet has stopped and a diet of weight maintenance will be provided. This protocol will be implemented in the nutrition department of the Pitié Salpétrière Hospital in Paris, within the Centre de Recherche en Nutrition Humaine d'Ile-de-France, where patients will be followed on the clinical, biological and histological levels. Evaluation will include medical history, physical, and nutritional evaluations. They will be excluded of the protocol if they had evidence of acute or chronic inflammatory disease, infectious diseases, cancer and/or known alcohol consumption (> 20g per day), as well as other causes of liver, kidney or heart diseases. Physical evaluation will include weight, height, measures of waist/hip ratio, measure of blood pressure. At each time point, body composition will be measured by dual-energy X-ray absorptiometry performed with a total body scanner (Hologic QDR 2500 densitometer). Resting metabolic rate will be evaluated after a one-hour resting period in supine position. Oxygen consumption (VO2) and carbon dioxide production (VCO2), monitored over 30 min by using an open-circuit ventilated-canopy system (Deltatrac II monitor, Datex Instrumentarium Corp., Helsinki, Finland) calibrated with a reference gas. Blood samples will be obtained systematically for biological parameters including lipids (cholesterol, HDL-Chol, TG), insulin and glucose values and OGTT (enabling the determination of insulin sensitivity parameters, adipokines and inflammatory parameters such as leptin, adiponectin, IL-6, TNF alpha, SAA, hsCRP. Serum will be kept for all supplementary measures. The histopathological evaluation of subcutaneous adipose tissue will be performed to evaluate the adipocyte size and the degree of tissue inflammation. Stools samples will be collected for metagenomic studies.

In addition, blood, urine and fecal water samples will be collected and frozen for subsequent metabonomic analysis, and fecal samples for metaproteomic assessment of the microbiota.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BMI 27 to 38 kg/m2
  • age: 25 to 65 years.
  • non diabetic subjects
  • fasting glycemia < 1,26 g/l

Exclusion criteria

  • SGOT ou SGPT > 2.5x normale
  • Glycemia > 1,26 g/l
  • any other health problem or chronic treatment

Treatment and study plan

Caloric transition

Other

6 week low calorie diet followed by 6 week stabilization period

Primary outcomes

  1. weight loss

  2. intestinal microbiota genes

    identify new intestinal microbiota at basal levels and follow their evolution during the dietary program by using a sequence based method (SOLiD™ System: a massively sequencing platform).

  3. Body fat mass

    using dual-energy X-ray absorptiometry performed with a total body scanner (Hologic QDR 2500 densitometer)

  4. Food intake

    using 7 day dietary records at each time point

Secondary outcomes

  1. plasma glucose

  2. adipose tissue genes

    Microarray

Sponsors and collaborators

Lead sponsor

Ceprodi S.A. Kot

Industry

Collaborators

  • Assistance Publique - Hôpitaux de Paris
  • Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
  • Institut National de la Santé Et de la Recherche Médicale, France
  • Pierre and Marie Curie University

Registry information

Acronym: Micro-Obes

Important dates

Study start
2008
Primary completion
2009
Study completion
2011
First posted
Mar 14, 2011
Registry last updated
Mar 14, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.